What is Perspectum?
Perspectum operates at the intersection of advanced digital technology and clinical medicine. The company specializes in developing sophisticated tools that assist clinicians in managing complex patient populations, specifically those suffering from chronic metabolic diseases, multi-organ pathologies, and various forms of cancer. By leveraging proprietary digital technologies, Perspectum provides actionable insights that improve diagnostic accuracy and treatment efficacy. Its global footprint allows the firm to integrate seamlessly into diverse healthcare ecosystems, positioning it as a critical partner for hospitals and medical institutions seeking to modernize their approach to chronic disease management through data-driven, non-invasive diagnostic platforms.
How much funding has Perspectum raised?
Perspectum has raised a total of $90.9M across 2 funding rounds:
Series B
$35.9M
Series C
$55M
Series B (2020): $35.9M with participation from Oxford University, Oxford Sciences Enterprises, HealthQuest Capital, and Puhua Capital
Series C (2023): $55M led by Oppenheimer Holdings
Key Investors in Perspectum
Oxford Sciences Enterprises
An independent investment firm established to build and fund transformational businesses through a unique partnership with the University of Oxford.
HealthQuest Capital
A growth equity firm providing capital to companies that are transforming healthcare through innovations in medical devices, technologies, and diagnostics.
Puhua Capital
An early-stage growth-equity firm based in China that provides industry resources, management expertise, and strategic investment funds.
What's next for Perspectum?
With the recent influx of capital, Perspectum is well-positioned to accelerate its research and development pipeline and expand its commercial reach. The strategic focus will likely center on deepening the clinical utility of its existing diagnostic suite while exploring new therapeutic areas where digital intervention can yield superior patient outcomes. As the company transitions into a more mature phase of its lifecycle, the emphasis will shift toward scaling operations and strengthening its competitive moat in the global medical technology market. Investors remain optimistic that the firm's unique combination of academic research roots and commercial agility will continue to drive significant advancements in healthcare delivery and diagnostic precision.
See full Perspectum company page
